FDA clears first-of-a-kind device for brain cancer

(AP) -- Medical device maker Novocure says it has received U.S. approval for a first-of-a-kind treatment which fights cancerous brain tumors using electrical energy fields.

The Food and Drug Administration has approved the device for patients with aggressive brain cancer that has returned after treatment with chemotherapy. Patients with recurring brain cancer usually live only a few months.

For decades doctors have treated cancer with drugs, and surgery. Novocure's NovoTTF offers a fourth approach. The portable device uses electric fields to disrupt the division of that allows tumors to grow. It sends the signals through four electrodes which are taped to the patient's head.

A 237-patient study showed that people using the device lived about as long as those taking . However, patients had significantly fewer side effects.


Explore further

TTF and chemotherapy increase survival for patients with advanced non-small cell lung cancer

©2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: FDA clears first-of-a-kind device for brain cancer (2011, April 15) retrieved 5 August 2020 from https://medicalxpress.com/news/2011-04-fda-first-of-a-kind-device-brain-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments